PapersFlow Research Brief
Biotechnology and Related Fields
Research Guide
What is Biotechnology and Related Fields?
Biotechnology and Related Fields is the interdisciplinary research area that develops and applies biological systems, organisms, and biomolecular knowledge to create health-relevant products and processes, with particular attention to innovation pathways, drug discovery productivity, and translation through industry and partnerships.
This topic cluster contains 150,590 works and is described as focusing on global health biotechnology, emerging markets, and the roles of innovation, entrepreneurship, capacity building, intellectual property, and public–private partnerships in developing countries. "Drug Discovery: A Historical Perspective" (2000) frames biotechnology’s modern trajectory as increasingly guided by pharmacology and the clinical sciences alongside molecular biology and genomics. "Can the pharmaceutical industry reduce attrition rates?" (2004) and "How to improve R&D productivity: the pharmaceutical industry's grand challenge" (2010) formalize biotechnology’s translational bottlenecks as problems of clinical attrition and R&D productivity rather than only scientific discovery.
Topic Hierarchy
Research Sub-Topics
Health Biotechnology Innovation in Developing Countries
Researchers study ecosystems fostering biotech drug and vaccine development in emerging markets, including local R&D capabilities and technology transfer. They analyze case studies from India, Brazil, and Africa.
Public-Private Partnerships in Biotechnology
This area examines governance, risk-sharing, and performance of PPPs in health biotech projects like vaccine production and diagnostics. Studies evaluate contract designs and scaling impacts in low-income settings.
Intellectual Property in Global Health Biotechnology
Research explores TRIPS flexibilities, compulsory licensing, and patent landscapes affecting biotech access in developing countries. It covers open innovation models and technology pooling mechanisms.
Biotech Entrepreneurship and Capacity Building
Studies focus on startup ecosystems, venture financing, and skill development for biotech firms in emerging markets. They assess incubators, regulatory harmonization, and human capital investments.
Science-Based Health Innovation in Emerging Markets
Researchers investigate translation of basic science into marketable health products via global collaborations and local adaptation. Topics include biosimilars development and clinical trial capacities.
Why It Matters
Biotechnology’s public-health impact is tightly coupled to whether discoveries can be translated into reliable medicines and biologics at scale, which makes R&D productivity and clinical attrition central practical constraints. Kola and Landis (2004) in "Can the pharmaceutical industry reduce attrition rates?" treated attrition reduction as an industry-level problem, directly linking biotechnology pipelines to the probability of producing approved therapies. Paul et al. (2010) in "How to improve R&D productivity: the pharmaceutical industry's grand challenge" positioned productivity as a “grand challenge,” emphasizing that scientific advances alone do not guarantee more effective therapeutics without better development strategies and decision-making. As a concrete example of downstream utility, "The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals" (1990) documents more than 10,000 monographs in a single reference volume, illustrating how biotechnology-adjacent innovation depends on standardized, accessible knowledge about chemicals, drugs, and biologicals for research, development, and clinical translation.
Reading Guide
Where to Start
Start with Drews (2000), "Drug Discovery: A Historical Perspective," because it gives a compact, field-level narrative of how drug research evolved and why molecular biology and genomics changed discovery priorities in modern biotechnology.
Key Papers Explained
Drews (2000) in "Drug Discovery: A Historical Perspective" provides the historical and conceptual backdrop for why biotechnology became intertwined with pharmacology and clinical science. Kola and Landis (2004) in "Can the pharmaceutical industry reduce attrition rates?" then narrows the focus to pipeline failure as a key limiter of therapeutic output. Paul et al. (2010) in "How to improve R&D productivity: the pharmaceutical industry's grand challenge" broadens this into a systems problem of productivity, connecting scientific choice, development strategy, and organizational decision-making. For a translation-oriented lens on how scientific facts and technologies become durable in society, Latour (1987) in "Science in action : how to follow scientists and engineers through society" complements the pipeline papers by emphasizing institutions, documentation, and networks. For biochemical depth that can underwrite target and mechanism thinking, Tabor and Tabor (1984) in "POLYAMINES" exemplifies how foundational molecular knowledge feeds applied biotechnology programs.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Using only the provided list, the most direct “frontier” directions are methodological rather than tied to specific new modalities: (i) improving decision frameworks for development under uncertainty as implied by the productivity and attrition focus of Paul et al. (2010) and Kola and Landis (2004), and (ii) strengthening translation pathways by explicitly analyzing the socio-technical conditions of adoption and stabilization described by Latour (1987). A practical advanced exercise is to take a biotechnology case (e.g., a therapeutic program) and explicitly map its evidence, stakeholders, documents, and institutional dependencies using "Science in action : how to follow scientists and engineers through society" (1987), then identify where attrition and productivity constraints described in 2004 and 2010 would likely arise.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Science in action : how to follow scientists and engineers thr... | 1987 | — | 9.0K | ✕ |
| 2 | Recent Progress in High-Order Residual-Based Compact Schemes f... | 2015 | HAL (Le Centre pour la... | 6.7K | ✓ |
| 3 | Pandora's Hope: Essays on the Reality of Science Studies | 2000 | Contemporary Sociology... | 5.1K | ✕ |
| 4 | The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biol... | 1990 | Annals of Internal Med... | 4.5K | ✕ |
| 5 | Can the pharmaceutical industry reduce attrition rates? | 2004 | Nature Reviews Drug Di... | 4.1K | ✕ |
| 6 | How to improve R&D productivity: the pharmaceutical indust... | 2010 | Nature Reviews Drug Di... | 3.4K | ✕ |
| 7 | POLYAMINES | 1984 | Annual Review of Bioch... | 3.0K | ✕ |
| 8 | Stastical Decision Theory and Bayesian Analysis. | 1988 | Journal of the America... | 2.9K | ✕ |
| 9 | Drug Discovery: A Historical Perspective | 2000 | Science | 2.7K | ✕ |
| 10 | The Low-Density Lipoprotein Pathway and its Relation to Athero... | 1977 | Annual Review of Bioch... | 2.5K | ✕ |
In the News
Biotech Funding 2025 Tracker: Follow the Latest Raises ...
**Multiple biotech companies are advancing into Phase I to III trials, reflecting a funding cycle that likely favors clinical readiness and scalable platforms.**
Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M
Nominations are now open for the Fierce Outsourcing Awards - Submit today** Biotech # Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds
Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration
Eli Lilly plans to expand its hearing loss therapy pipeline by collaborating with Seamless Therapeutics to apply the company’s next-generation gene-editing approach, based on programmable recombina...
The Biotech Landscape in 2025 and Beyond: Is a Rebound ...
The biotech industry stands at a crossroads. The interplay between innovation, policy changes, and pricing challenges will shape the future of biotech, influencing how companies navigate funding, r...
Bolstering Biotechnology in New York State
Medical University expertise and CORE Facilities as well as targeted commercialization resources. Additionally, CNYBAC clients are eligible to apply to Upstate Biotech Ventures, a partnership devel...
Code & Tools
## Biopython README file The Biopython Project is an international association of developers of freely available Python tools for computational m...
This is a list of implementations of deep learning methods to biology, originally published on Follow the Data . There is a slant towards genomics ...
Community-curated list of software packages and data resources for single-cell, including RNA-seq, ATAC-seq, etc. ### License MIT license
techno-economic analysis, and life cycle assessment of biorefineries under uncertainty[[1]] . BioSTEAM is built to streamline and automate early-st...
> > Bioinformatics is an interdisciplinary field that develops methods and software tools for understanding biological data. — > Wikipedia
Recent Preprints
Nature Biotechnology
SubjectAll SubjectsAll SubjectsBiochemistryBiological techniquesBiophysicsBiotechnologyCancerCell biologyChemical biologyComputational biology and bioinformaticsDevelopmental biologyDrug discoveryE...
Biotechnology and Bioengineering - Wiley Online Library
_Biotechnology and Bioengineering_ provides an international forum for biotech researchers. As the first biotechnology journal dedicated to the field, our publication has contributed significantly ...
Journal of Advances in Biology & Biotechnology
**Journal of Advances in Biology & Biotechnology (ISSN: 2394-1081)** aims to publish high quality papers ( Click here for Types of paper ) in all areas of ‘Biology & Biotechnology’. By not excludin...
Frontiers in Bioengineering and Biotechnology
### Biohydrogel-Based Biomaterials for Next-Generation Tissue Repair * Zhang Wencan * Fei-Long Wei * Baoshuai Bai * Wenhan Wang * **129**views] * [ Submission open ### Advancing Soft-Tissue Biomat...
Electronic Journal of Biotechnology
**_Electronic Journal of Biotechnology_** is an international, scientific open access journal that publishes high-quality research from all areas related to biotechnology.
Latest Developments
Recent developments in biotechnology research for 2026 include breakthroughs in AI-enabled drug development, next-generation gene editing such as prime editing and in vivo base editing targeting cardiovascular diseases, and advancements in human-relevant testing models and spatial biology platforms, reflecting a significant shift towards personalized medicine and scalable biological analysis (ZAGENO, biopharmadive, biopharmaapac, MIT Technology Review, Nature Biotechnology).
Sources
Frequently Asked Questions
What is meant by “Biotechnology and Related Fields” in the context of health and public health?
Biotechnology and Related Fields refers to research and development that applies biological knowledge to create health-relevant products and processes, while also studying how those products move through discovery, development, and implementation. In this topic cluster, the provided description emphasizes global health biotechnology, emerging markets, and translation mechanisms such as entrepreneurship, capacity building, intellectual property, and public–private partnerships.
How do researchers analyze why some biotechnologies succeed while others fail to translate into therapies?
A common approach is to study the development pipeline as a socio-technical process rather than only a laboratory process. Latour (1987) in "Science in action : how to follow scientists and engineers through society" provides a framework for tracing how scientific and engineering claims are stabilized through networks, documents, and institutions, which can be applied to biotechnology translation.
Why is clinical attrition a central concern in biotechnology R&D?
Attrition matters because it determines how often promising candidates fail during development, limiting the number of therapies that reach patients. "Can the pharmaceutical industry reduce attrition rates?" (2004) directly frames attrition reduction as a key industry problem affecting the output of drug development pipelines.
Which papers in the provided list are most useful for understanding drug discovery and R&D productivity in biotechnology?
"Drug Discovery: A Historical Perspective" (2000) provides a field-level view of how drug research evolved and how molecular biology and genomics influenced modern discovery. "How to improve R&D productivity: the pharmaceutical industry's grand challenge" (2010) and "Can the pharmaceutical industry reduce attrition rates?" (2004) focus on productivity and attrition as core constraints on biotechnology’s translational impact.
Which reference work supports practical biotechnology and pharmaceutical research with standardized substance information?
"The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals" (1990) is described as a one-volume encyclopedia containing more than 10,000 monographs. Each monograph is a concise description of a substance or closely related compounds, supporting consistent identification and use across research and development.
How do foundational biochemical topics connect to biotechnology applications?
Biotechnology frequently depends on deep mechanistic understanding of biomolecules and pathways that can be targeted, engineered, or measured. Tabor and Tabor (1984) in "POLYAMINES" synthesizes knowledge about polyamines, offering biochemical grounding that can inform applications ranging from metabolism-focused therapeutics to biomolecular engineering strategies.
Open Research Questions
- ? How can biotechnology organizations measurably reduce clinical attrition across development stages, as posed by "Can the pharmaceutical industry reduce attrition rates?" (2004), without sacrificing novelty or patient relevance?
- ? Which operational and scientific changes most effectively improve end-to-end R&D productivity under the constraints discussed in "How to improve R&D productivity: the pharmaceutical industry's grand challenge" (2010)?
- ? How should biotechnology researchers map and evaluate the socio-technical networks that determine whether an innovation becomes a stable, transferable technology, following the approach in "Science in action : how to follow scientists and engineers through society" (1987)?
- ? How can historical lessons about the drivers of drug discovery in "Drug Discovery: A Historical Perspective" (2000) be converted into actionable heuristics for selecting targets, modalities, and development strategies today?
- ? Which biochemical control points emphasized in "POLYAMINES" (1984) are most tractable for intervention, and what evidence standards are needed to translate such mechanisms into robust therapeutic programs?
Recent Trends
The provided topic data emphasizes scale and translational focus: the cluster contains 150,590 works and is characterized by global health biotechnology, emerging markets, and mechanisms such as entrepreneurship, capacity building, intellectual property, and public–private partnerships.
Within the provided paper list, a notable through-line is the shift from discovery-centric narratives to pipeline-centric constraints: "Drug Discovery: A Historical Perspective" highlights the growing influence of molecular biology and genomics on discovery, while "Can the pharmaceutical industry reduce attrition rates?" (2004) and "How to improve R&D productivity: the pharmaceutical industry's grand challenge" (2010) center attrition and productivity as dominant practical limitations on biotechnology’s ability to deliver therapies.
2000As an indicator of the field’s reliance on standardized, reusable knowledge artifacts, "The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals" is described as containing more than 10,000 monographs, reflecting the continued importance of curated reference infrastructure for research and development.
1990Research Biotechnology and Related Fields with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Biotechnology and Related Fields with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers